✦ LIBER ✦

C-reactive protein and monitoring the activity of Crohn’s disease

✍ Scribed by Levent Filik; Ulku Dagli; Aysel Ulker

Publisher: Springer Healthcare Communications
Year: 2006
Tongue: English
Weight: 214 KB
Volume: 23
Category: Article
ISSN: 0741-238X
DOI: 10.1007/bf02850054

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

C-reactive protein: Informative or misle

C-reactive protein: Informative or misleading marker of Crohn's disease?

✍ Denis Franchimont 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

I n a recent study, the Radford-Smith group addressed the important question of whether it was possible to identify and characterize patients with normal or low serum Creactive protein (CRP) levels in a prospective cohort of patients with active Crohn's disease (as per the criteria of the Crohn's Di

Infliximab and the risk of latent viruse

Infliximab and the risk of latent viruses reactivation in active Crohn's disease

✍ Alessandro Lavagna; Massimiliano Bergallo; Marco Daperno; Raffaello Sostegni; Cr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Background: Infliximab is used for refractory Crohn's disease but there are concerns regarding long-term safety. Recently, JCpolyomavirus (JCV) was studied after 3 cases of progressive multifocal leukoencephalopathy (PML) were found after treatment with natalizumab. The aim of this study was to

Assessment of endoscopic activity index

Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level

✍ Marie-Armelle Denis; Catherine Reenaers; Fernand Fontaine; Jacques Belaïche; Edo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Background: Patients with clinically active Crohn's disease (CD), defined by a Crohn's Disease Activity Index (CDAI) Ͼ150, may have normal C-reactive protein (CRP) serum levels. In such cases, it is difficult to know whether these patients have really active disease or rather functional symptoms. Th

Fecal calprotectin, lactoferrin, and end

Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease

✍ Taina Sipponen; Erkki Savilahti; Päivi Kärkkäinen; Kaija-Leena Kolho; Hannu Nuut 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

Background: Fecal calprotectin and lactoferrin are promising noninvasive biomarkers for intestinal inflammation. In Crohn's disease (CD), during anti-TNF-alpha (TNF-␣) treatment, the clinical significance of these markers has, however, been insufficiently explored. Methods: Among CD patients receiv

Factors predicting the outcome of diseas

Factors predicting the outcome of disease activity assessment in Crohn's disease

✍ Henrik Stjernman; Curt Tysk; Sven Almer; Magnus Ström; Henrik Hjortswang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

Background: The Crohn's Disease Activity Index (CDAI) has become the gold standard for assessment of disease activity in CD. This study investigated the relationship between CDAI and the physicians' global assessment of disease activity (PGA) and whether different demographic and disease-related fac

Serum lipopolysaccharide-binding protein

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease

✍ Peter Laszlo Lakatos; Lajos Sandor Kiss; Karoly Palatka; Istvan Altorjay; Peter 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 308 KB 👁 1 views

## Background: In inflammatory bowel disease (ibd), enhanced inflammatory activity in the gut is thought to increase the risk of bacterial translocation and endotoxemia. in the present study we investigated the association between serum level of lipopolysaccharide-binding protein (lbp), soluble cd1